Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ASPRIA
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- NCT04434040 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on ASPRIA (atezolizumab and sacituzumab govitecan in Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ASPRIA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 3 | |
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; Triple Negative Breast Cancer; Residual Cancer; Circulating Tumor DNA
- Interventions
- Atezolizumab; Sacituzumab govitecan
- Arms
- Atezolizumab and Sacituzumab govitecan · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Rate of undetectable circulating tumor cfDNA- 6 Cycles
- Sponsor
- Dana-Farber Cancer Institute with Genentech, Inc., Stand Up To Cancer
- Start
- Jul 2, 2020
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04434040 · updated May 4, 2026